Trading Options with an Edge
Select Page

FATE

Search by
TICKER SYMBOL

Fate Therapeutics Inc

Sector: Manufacturing
Industry: Biological Product (except Diagnostic) Manufacturing

22.1

-1

(-4.329%)

Volume:

253,843

52 week range:

17.1 - 66.56

Market Cap:

2.144B

Company Description:

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company's immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company's immuno-regulatory product candidates include ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease. Fate Therapeutics is headquartered in San Diego, CA.